Supernus Pharmaceuticals (LTS:0LB2) Net Income (Continuing Operations) : $-15.5 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Supernus Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $0.1 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.5 Mil.

Supernus Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Supernus Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Net Income (Continuing Operations) Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

113.06

126.95

53.42

60.71

1.32

Supernus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															16.95	-0.83	-15.98	1.18	0.12

Supernus Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.5 Mil.

Supernus Pharmaceuticals (LTS:0LB2) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Supernus Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (LTS:0LB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (LTS:0LB2) Headlines

No Headlines